Convierte Checkmate CHECK a VitaStem VITASTEM

Chess remains one of the most widely played and culturally significant games in history. With over 605.0 million players globally and over $2.5 billion in market value, its recent resurgence, driven by digital platforms, live streaming, and global accessibility, has brought the game to new audiences. Yet despite this momentum, the digital chess experience has remained largely unchanged. It continues to be the same game, with the same rules and mechanics. Anichess looks to modernize chess and reimagine the timeless game. By integrating spell-based mechanics, digital ownership, and player-driven governance, it reimagines chess as an interactive, evolving ecosystem. Anichess transforms the game as a new title that looks to advance chess adoption, giving seasoned players a twist to the game they love and empowering newer players by giving them an even playing field to enter the game and test their skills.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.